HIV transmissions from a window-period platelet donation

American Journal of Clinical Pathology

Volumn 116, Issue 4, 2001, Pages 562-566

  Kopko, Patricia M ^a   Fernando, Leonor P ^a   Bonney, Erica N ^a   Freeman, Jed L ^a   Holland, Paul V ^a  

^a Sacramento Medical Foundation Blood Center   (United States)

Author keywords

AIDS; HIV; HIV transmission; Nucleic acid testing; Platelets; Polymerase chain reaction; Transfusion

Indexed keywords

ANTIGEN P24; VIRUS RNA;

ADULT; ANTIGEN DETECTION; ARTICLE; BLOOD DONOR; CASE REPORT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MALE; NUCLEIC ACID ANALYSIS; PRIORITY JOURNAL; RNA ANALYSIS; SAMPLING; SEROCONVERSION; THROMBOCYTE; VIRUS TRANSMISSION;

ADULT; AGED; ANTIBODIES, VIRAL; BLOOD DONORS; BLOTTING, WESTERN; HIV; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HIV-2; HUMANS; MALE; MIDDLE AGED; PLATELET TRANSFUSION; PLATELETPHERESIS; RNA, VIRAL; TIME FACTORS;

EID: 0035736515     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/GBLA-NL8D-3277-XUP1     Document Type: Article

References (15)

1. Schreiber GB, Busch MP, Kleinman SH, et al, for the Retrovirus Epidemiology Donor Study. The risk of transfusion-transmitted viral infections. N Engl J Med. 1996;334:1685-1690.
2. Busch MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med. 1997;102:117-124.
3. Petersen LR, Satten GA, Dodd R, et al. Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. Transfusion. 1994;34:283-289.
4. Busch MP, Lee LLL, Satten GA, et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion. 1995;35:91-97.
5. AuBuchon JP, Birkmeyer JD, Busch MP. Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood. Tranfusion. 1997;37:45-51.
6. Eddy DM. Screening for cervical cancer. Ann Intern Med. 1990;113:214-226.
7. Blood Products Advisory Committee, 67th meeting. September 14, 2000; Gaithersburg, MD. Transcript available at www.fda.gov/ohrms/dockets/ac/cber00.htm.
8. Busch MP, Stramer SL. Sensitivity and validity of HIV-screening methods. Infusion Ther Transfusion Med. 1998;25: 5-8.
9. Schreiber G, Glynn S, Busch M, et al, for the Retrovirus Epidemiology Donor Study. Delayed donations in repeat blood donors who HIV seroconvert may explain low p24 antigen yield [abstract]. Transfusion. 1997;37:109S.
10. Glynn S, Kleinman S, Schreiber G, et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in the US blood donors, 1991 to 1996. JAMA. 2000;284:229-235.
11. Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases. Transfusion. 2000;40:143-159.
12. Murthy KK, Henrad DR, Eichberg JW, et al. Redefining the HIV-infectious window period in the chimpanzee model: evidence to suggest that viral nucleic acid testing can prevent blood-borne transmission. Transfusion. 1999;39:688-693.
13. Ling A, Robbins K, Brown T, et al. Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period. JAMA. 2000:284;210-214.
14. Schwartz DWM, Zerlauth G, Mayr WR. Detection of a window-period donation by pool-PCR testing for HIV [abstract]. Vox Sang. 2000;78S:0064.
15. Katzenstein T, Dickmeiss E, Aladdin H, et al. Failure to develop HIV infection after receipt of HIV-contaminated blood and postexposure prophylaxis. Ann Intern Med. 2000:133:31-34.